Kim Ekroos

This inventor holds 17 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 7 EPO patents. Top assignee: Zora Biosciences Oy. Active years: 2015-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kim Ekroos. Retrieved from https://idiyas.com/inventor/kim-ekroos

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 4)

% Patents Active = 88.2

CIPO Patents = 2

EPO Patents = 7 (Patent Applications = 14)

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 12(Granted Patents)

Location History:

Espoo, FI (2017)
Helsinki, FI (2015 - 2024)

Company Filing History:

17 out of 26

Zora Biosciences Oy

patents

Years Active: 2015-2025

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12270816 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2025-04-08),

2. 12025623 - Lipidomic biomarkers for atherosclerosis and cardiovascular disease (2024-07-02),

3. 10955427 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2021-03-23),

4. 10551394 - Lipidomic biomarkers for atherosclerosis and cardiovascular disease (2020-02-04),

5. 10261101 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2019-04-16),

6. 9863965 - Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment (2018-01-09),

7. 9857386 - Lipidomic biomarkers for atherosclerosis and cardiovascular disease (2018-01-02),

8. 9841431 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2017-12-12),

9. 9664698 - Biomarkers for sensitive detection of statin-induced muscle toxicity (2017-05-30),

10. 9541565 - Biomarkers for sensitive detection of statin-induced muscle toxicity (2017-01-10),

11. 9459265 - Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment (2016-10-04),

12. 9459264 - Lipidomic biomarkers for atherosclerosis and cardiovascular disease (2016-10-04),

13. 9423406 - Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment (2016-08-23),

14. 9201080 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2015-12-01),

15. 9052328 - Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment (2015-06-09),

Title: Innovations in Cardiovascular Disease Prediction by Kim Ekroos

Introduction

Kim Ekroos is a prominent inventor based in Helsinki, Finland, known for his significant contributions to the field of cardiovascular disease research. With a total of 17 patents to his name, Ekroos has focused on developing innovative methods for predicting and diagnosing cardiovascular conditions through lipidomic biomarkers.

Latest Patents

Among his latest patents, Ekroos has developed a method for identifying high-risk coronary artery disease patients. This invention provides a way to predict severe cardiovascular disease complications, such as acute myocardial infarction (AMI) or cardiovascular death, by detecting lipid concentrations or ratios in biological samples. The method compares these findings to a control and has identified specific lipid markers that are more sensitive and specific than currently utilized clinical markers. Additionally, the invention includes antibodies targeting these lipids, which can be used for predicting, diagnosing, preventing, and treating cardiovascular complications. Another notable patent focuses on diagnosing and predicting atherosclerosis and cardiovascular disease through similar lipidomic approaches, further enhancing the accuracy of clinical assessments.

Career Highlights

Ekroos is currently associated with Zora Biosciences Oy, where he continues to innovate in the field of lipidomics and cardiovascular health. His work has been instrumental in advancing the understanding of lipid biomarkers and their applications in clinical settings.

Collaborations

Throughout his career, Ekroos has collaborated with notable colleagues, including Reijo Laaksonen and Reini Hurme, contributing to a rich environment of research and innovation.

Conclusion

Kim Ekroos stands out as a leading inventor in the realm of cardiovascular disease research, with his innovative patents paving the way for improved diagnostic and predictive methods. His contributions are vital in the ongoing battle against cardiovascular diseases, showcasing the importance of lipidomic research in modern medicine.

Profile summary based on public USPTO records.